27 April 2015
China authorities at the highest level are acting on legislation that would, among other things, decentralize drug industry regulation and free some price controls.
The State Council, China's cabinet, is meeting this week to consider bills and amendments intended to give some regulatory relief to several industries, including pharmaceutical.
Instead of dealing with one centralized regulatory agency, drugmakers would be required to get their certificates to operate at the provincial level, according toXinhua, the state-owned news agency, which did not elaborate.
Other legislative amendments would determine the prices that can be charged for drugs and some other products based on the market as well as the central government. The amendments suggest the changes would allow "competitive prices" for drugs.
One State Council official said, "Price administrative departments of the State Council will make supervising regulations, increasing supervision over prices, and deal with violators."
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Research calls for greater investment in Alzheimer’s clinical trials
03 May 2024
Stress impact on protein particle formation for monoclonal antibody formulation
03 May 2024
Health Ministry registered Russian drug for ankylosing spondylitis
02 May 2024
Production of finished drugs in Russia grew by 13.8%
02 May 2024